Decibel Therapeutics Expands World-Class Scientific Advisory Board
24 mai 2021 16h15 HE
|
Decibel Therapeutics, Inc.
BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Present at the UBS Global Healthcare Virtual Conference
19 mai 2021 08h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, May 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Reports First Quarter 2021 Financial Results and Corporate Update
13 mai 2021 17h05 HE
|
Decibel Therapeutics, Inc.
– Established cGMP manufacturing and development agreement with Catalent for otoferlin dual-vector gene therapy, DB-OTO – – Successfully completed the second tranche of an oversubscribed Series D...
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy 24th Annual Meeting
28 avr. 2021 08h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
08 avr. 2021 08h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
29 mars 2021 16h05 HE
|
Decibel Therapeutics, Inc.
-Successfully completed an oversubscribed Series D financing and upsized Initial Public Offering raising approximately $220.1M in gross proceeds- -Established development and manufacturing agreement...
Decibel Therapeutics Added to Russell 2000 Index
22 mars 2021 08h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, March 22, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX) (“Decibel”), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments...
Decibel Therapeutics to Present at the Barclays Global Healthcare Conference
04 mars 2021 08h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations
24 févr. 2021 07h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage company developing treatments to restore and improve hearing and balance, presented preclinical data...
Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference
19 févr. 2021 07h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...